Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity

Abstract

We established novel in vitro HNSCC cancer organoid lines retaining many properties of the original tumors from they were derived. These organoids can predict in vivo drug sensitivity and may represent useful tools to develop precision treatments for HNSCC.